Dvorák I, Blaha M, Nĕmcová H
Department of Medicine II, Masaryk University, Brno, Czechoslovakia.
Am J Hypertens. 1991 Feb;4(2 Pt 2):144S-146S. doi: 10.1093/ajh/4.2.144s.
After three months of treatment with isradipine, 20 patients with mild hypertension had reduced their resting blood pressure (BP) from 157/103 to 132/85 mm Hg and their BP during isometric exercise from 192/124 to 166/105 mm Hg. The isradipine dose necessary to normalize BP (both at rest and post-exercise) was 1.25 mg twice daily (2 x 1/2 tablet) in 50% of patients and 2.5 mg twice daily (2 x 1 tablet) in 25%. In the remaining 25% of patients, isradipine was combined with 1 mg/day bopindolol. There were virtually no accompanying side effects; in particular, reflex tachycardia was negligible or absent. It is concluded that isradipine is a reliable antihypertensive treatment in mild-to-moderate hypertension.
使用伊拉地平治疗三个月后，20例轻度高血压患者的静息血压从157/103降至132/85毫米汞柱，等长运动时的血压从192/124降至166/105毫米汞柱。使血压（静息和运动后）恢复正常所需的伊拉地平剂量，50%的患者为每日两次1.25毫克（2×1/2片），25%的患者为每日两次2.5毫克（2×1片）。其余25%的患者，伊拉地平与每日1毫克的波吲洛尔联合使用。几乎没有伴随的副作用；特别是反射性心动过速可忽略不计或不存在。结论是伊拉地平是轻至中度高血压的可靠抗高血压治疗药物。
